FDA observations at Bachupally biologics facility
US FDA pre-approval inspection resulted in 9 observations. Management believes they are addressable but could delay biosimilar approvals if not resolved timely.
high · management_commentary
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
India business growth trajectory uncertainty
Despite guidance for double-digit growth by year-end, India business has been range-bound for several quarters. Analyst questioned the timeline for material step-up.
medium · analyst_questionPrice erosion in US generics
Price erosion remains a headwind, though moderating. Management noted it fluctuates between high single-digit to low double-digit, impacting revenue growth.
medium · data_observation